Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Global Manager Regulatory Affairs, Oncology
View:
Post by scarlet1967 on Oct 05, 2022 9:01pm

Global Manager Regulatory Affairs, Oncology

I leave it for you to interpret why THTX is looking for a Global Manager Regulatory Affairs, Oncology!!! 

 

 

 

 

“The incumbent provides support to the Director, Global Regulatory Affairs and Pharmacovigilance with all submissions filed to the health authorities (e.g. FDA, Health Canada, European Medicines Agency) aligned with the regulatory strategies in support of these filings; assists with information requests for dossiers under active review; and ensures that marketing authorizations are g r a n t e d a n d maintained as per applicable Federal Regulations and Guidances in various jurisdictions and throughout the product(s) lifecycle.”

 

https://www.theratech.com/static-files/00e5c4e6-f2d6-4d33-95e4-929776d0c972

Comment by Biobob on Oct 05, 2022 9:18pm
Ok that's a good sign of things to come for Shure.
Comment by TH1902 on Oct 06, 2022 8:40am
Probably nothing...lol...exciting find scarlet, perhaps a protocol amendment on its way...
Comment by Wino115 on Oct 06, 2022 9:50am
This is important because a company that needs to hold tight reins on it's cash position would need to run any new position of significance by it's Board of Directors. In other words, this is not just one person's decision to build an oncology regulatory function. It's the management teams and BOD's assessment that there is a reasonable thesis to support this need. Having more ...more  
Comment by Biobob on Oct 06, 2022 9:55am
That makes 3 of us... surprising no other comments on this find... a lag in the interpretation of clear positive indication that Th1902 is going somewhere and therof that POC has been accomplished... logically it would not make sense otherwhise... wake up market.
Comment by SPCEO1 on Oct 06, 2022 10:53am
Add it to the series of hints we have been given in the run-up to next Thursday's conference call. And it seems to me to be a pretty big hint that something positive is happening with TH-1902. It is hard to know exactly what they will choose to share next week about TH-1902 but it has to be good info on some level. 
Comment by Biobob on Oct 06, 2022 11:20am
I mean do you hire a guy for Oncology if you are going to DOA and specify P2/P3... also if you are Paul Lvesques (former senior VP at Pfizer HO, NYC) that you leave a top job for little Thera and than put up your name (not Christian) on that KEY slide in front of a NYC audience (his former turf).. his name under that statement that will put you on a pedestal.  Makes no sense that this is a ...more  
Comment by JohnBelg on Oct 06, 2022 12:03pm
Does the Montral Minnow hold the key to the door of the cancer cell?
Comment by JohnBelg on Oct 06, 2022 12:04pm
Montreal Minnow.
Comment by Biobob on Oct 06, 2022 12:26pm
Most great discovery arrived trought University programs... Big does'nt equate success in discovery.... 
Comment by jfm1330 on Oct 06, 2022 12:35pm
From the job offer. It is quite clear what they are aiming at. This is for serious oncology companies. Direct experience with FDA Project Orbis and/or Project Optimus is an important asset https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus
Comment by palinc2000 on Oct 06, 2022 12:15pm
Maybe they are asking for applicants just in case ...and also bcause they expect that it wil' take a long time to find a candidate with the required quslifications If they in fact go further and actually hire for that position then I will increase my position depending on j what the  SP will be
Comment by scarlet1967 on Oct 06, 2022 4:41pm
This was endorsed by previous Regulatory Affairs Manager which either left or was let go in September so it seems they are looking for a similar expertise again adding the oncology parts to it. https://www.linkedin.com/feed/update/urn:li:activity:6983534790327029761?updateEntityUrn=urn%3Ali%3Afs_feedUpdate%3A%28V2%2Curn%3Ali%3Aactivity%3A6983534790327029761%29  
Comment by palinc2000 on Oct 07, 2022 9:26am
Thx for the clarification...Surprisinly already 19 applicants !..The new recruit will be based in New Jersey it seems but working remote Paul is probably thinking /hoping to recruit from Pfizer  
Comment by Joemare on Oct 06, 2022 12:50pm
If it's material, why not release a PR!  What's the problem????  Who are we kidding. This is onco + biotech. This industry thrives through PRs!!!  Come on, biotech 101! 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse